Report cover image

Pharmaceutical Contract Sales Outsourcing (CSO) Market (Therapeutic Area: Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others) - Europe Industry Analysis, Size, Share, Growth, Trends, an

Publisher Transparency Market Research Pvt. Ltd.
Published Jul 29, 2022
Length 181 Pages
SKU # TNPR17372899

Description

Pharmaceutical Contract Sales Outsourcing (CSO) Market (Therapeutic Area: Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market – Scope of Report
TMR’s report on the pharmaceutical contract sales outsourcing (CSO) market in Europe studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the pharmaceutical contract sales outsourcing (CSO) market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of pharmaceutical contract sales outsourcing (CSO) market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pharmaceutical contract sales outsourcing (CSO) market in Europe.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the pharmaceutical contract sales outsourcing (CSO) market in Europe.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the pharmaceutical contract sales outsourcing (CSO) market in Europe. These serve as valuable tools for existing market players as well as for entities interested in participating in the pharmaceutical contract sales outsourcing (CSO) market in Europe.

The report delves into the competitive landscape of the pharmaceutical contract sales outsourcing (CSO) market. Key players operating in the pharmaceutical contract sales outsourcing (CSO) market in Europe have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the pharmaceutical contract sales outsourcing (CSO) market profiled in this report.

Research Methodology
The research methodology is a combination of exhaustive primary and secondary research to analyze the pharmaceutical contract sales outsourcing (CSO) market.

Secondary Research

Secondary research included a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we referred to include, but are not limited to:

Company websites, presentations, annual reports, white papers, technical papers, product brochures
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
Veterinary Council of Europe
Europen Federation of Animal Health
Animal Welfare Board of Europe
Company Information
Statista
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of the research, we conducted in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents the bulk of research efforts, supplemented by extensive secondary research.

We conducted primary interviews with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who took part in the process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts
Key opinion leaders specializing in the market with respect to different industry verticals
Primary participants included, but are not limited to:

Bayer AG
Elanco Products Company
Merck & Co., Inc.
Ceva Sante Animale
Virbac SA

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter

Market Estimation: Market size estimations involved an in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we used modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Population, inflation rates, and others
Industry Indicators: Production data, R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived by taking into account drivers, restraints/challenges, opportunities prevailing in the market, and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise consumption data are the other pivotal factors considered to derive market forecasts.

Table of Contents

181 Pages
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Europe Healthcare Industry Overview
5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.3. COVID-19 Pandemic Impact on Industry (value chain and short /mid / long term impact)
6. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Service, 2017–2031
6.3.1. Personal Promotion
6.3.1.1. Promotional Sales Team
6.3.1.1.1. Dedicated Sales Team
6.3.1.1.2. Syndicated Sales Team
6.3.1.2. Key Account Management
6.3.1.3. Vacancy Management
6.3.2. Non-personal Promotion
6.3.2.1. Tele-detailing
6.3.2.2. Interactive E-detailing
6.3.2.3. Customer Service
6.3.2.4. Medical Science Liaisons
6.3.2.5. Patient Engagement Services
6.3.2.6. Others
6.3.3. Other Services
6.4. Market Attractiveness Analysis, by Service
7. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2017–2031
7.3.1. Cardiovascular Disorders
7.3.2. Oncology
7.3.3. Metabolic Disorders
7.3.4. Neurology
7.3.5. Orthopedic Diseases
7.3.6. Infectious Diseases
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Market Attractiveness Analysis, by Country/Sub-region
9. Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Service, 2017–2031
9.2.1. Personal Promotion
9.2.1.1. Promotional Sales Team
9.2.1.1.1. Dedicated Sales Team
9.2.1.1.2. Syndicated Sales Team
9.2.1.2. Key Account Management
9.2.1.3. Vacancy Management
9.2.2. Non-personal Promotion
9.2.2.1. Tele-detailing
9.2.2.2. Interactive E-detailing
9.2.2.3. Customer Service
9.2.2.4. Medical Science Liaisons
9.2.2.5. Patient Engagement Services
9.2.2.6. Others
9.2.3. Other Services
9.3. Market Value Forecast, by Therapeutic Area, 2017–2031
9.3.1. Cardiovascular Disorders
9.3.2. Oncology
9.3.3. Metabolic Disorders
9.3.4. Neurology
9.3.5. Orthopedic Diseases
9.3.6. Infectious Diseases
9.3.7. Others
9.4. Market Attractiveness Analysis
9.4.1. By Service
9.4.2. By Therapeutic Area
10. U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Service, 2017–2031
10.2.1. Personal Promotion
10.2.1.1. Promotional Sales Team
10.2.1.1.1. Dedicated Sales Team
10.2.1.1.2. Syndicated Sales Team
10.2.1.2. Key Account Management
10.2.1.3. Vacancy Management
10.2.2. Non-personal Promotion
10.2.2.1. Tele-detailing
10.2.2.2. Interactive E-detailing
10.2.2.3. Customer Service
10.2.2.4. Medical Science Liaisons
10.2.2.5. Patient Engagement Services
10.2.2.6. Others
10.2.3. Other Services
10.3. Market Value Forecast, by Therapeutic Area, 2017–2031
10.3.1. Cardiovascular Disorders
10.3.2. Oncology
10.3.3. Metabolic Disorders
10.3.4. Neurology
10.3.5. Orthopedic Diseases
10.3.6. Infectious Diseases
10.3.7. Others
10.4. Market Attractiveness Analysis
10.4.1. By Service
10.4.2. By Therapeutic Area
11. France Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Service, 2017–2031
11.2.1. Personal Promotion
11.2.1.1. Promotional Sales Team
11.2.1.1.1. Dedicated Sales Team
11.2.1.1.2. Syndicated Sales Team
11.2.1.2. Key Account Management
11.2.1.3. Vacancy Management
11.2.2. Non-personal Promotion
11.2.2.1. Tele-detailing
11.2.2.2. Interactive E-detailing
11.2.2.3. Customer Service
11.2.2.4. Medical Science Liaisons
11.2.2.5. Patient Engagement Services
11.2.2.6. Others
11.2.3. Other Services
11.3. Market Value Forecast, by Therapeutic Area, 2017–2031
11.3.1. Cardiovascular Disorders
11.3.2. Oncology
11.3.3. Metabolic Disorders
11.3.4. Neurology
11.3.5. Orthopedic Diseases
11.3.6. Infectious Diseases
11.3.7. Others
11.4. Market Attractiveness Analysis
11.4.1. By Service
11.4.2. Therapeutic Area
12. Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Service, 2017–2031
12.2.1. Personal Promotion
12.2.1.1. Promotional Sales Team
12.2.1.1.1. Dedicated Sales Team
12.2.1.1.2. Syndicated Sales Team
12.2.1.2. Key Account Management
12.2.1.3. Vacancy Management
12.2.2. Non-personal Promotion
12.2.2.1. Tele-detailing
12.2.2.2. Interactive E-detailing
12.2.2.3. Customer Service
12.2.2.4. Medical Science Liaisons
12.2.2.5. Patient Engagement Services
12.2.2.6. Others
12.2.3. Other Services
12.3. Market Value Forecast, by Therapeutic Area, 2017–2031
12.3.1. Cardiovascular Disorders
12.3.2. Oncology
12.3.3. Metabolic Disorders
12.3.4. Neurology
12.3.5. Orthopedic Diseases
12.3.6. Infectious Diseases
12.3.7. Others
12.4. Market Attractiveness Analysis
12.4.1. By Service
12.4.2. By Therapeutic Area
13. Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Service, 2017–2031
13.2.1. Personal Promotion
13.2.1.1. Promotional Sales Team
13.2.1.1.1. Dedicated Sales Team
13.2.1.1.2. Syndicated Sales Team
13.2.1.2. Key Account Management
13.2.1.3. Vacancy Management
13.2.2. Non-personal Promotion
13.2.2.1. Tele-detailing
13.2.2.2. Interactive E-detailing
13.2.2.3. Customer Service
13.2.2.4. Medical Science Liaisons
13.2.2.5. Patient Engagement Services
13.2.2.6. Others
13.2.3. Other Services
13.3. Market Value Forecast, by Therapeutic Area, 2017–2031
13.3.1. Cardiovascular Disorders
13.3.2. Oncology
13.3.3. Metabolic Disorders
13.3.4. Neurology
13.3.5. Orthopedic Diseases
13.3.6. Infectious Diseases
13.3.7. Others
13.4. Market Attractiveness Analysis
13.4.1. By Service
13.4.2. By Therapeutic Area
14. Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Service, 2017–2031
14.2.1. Personal Promotion
14.2.1.1. Promotional Sales Team
14.2.1.1.1. Dedicated Sales Team
14.2.1.1.2. Syndicated Sales Team
14.2.1.2. Key Account Management
14.2.1.3. Vacancy Management
14.2.2. Non-personal Promotion
14.2.2.1. Tele-detailing
14.2.2.2. Interactive E-detailing
14.2.2.3. Customer Service
14.2.2.4. Medical Science Liaisons
14.2.2.5. Patient Engagement Services
14.2.2.6. Others
14.2.3. Other Services
14.3. Market Value Forecast, by Therapeutic Area, 2017–2031
14.3.1. Cardiovascular Disorders
14.3.2. Oncology
14.3.3. Metabolic Disorders
14.3.4. Neurology
14.3.5. Orthopedic Diseases
14.3.6. Infectious Diseases
14.3.7. Others
14.4. Market Attractiveness Analysis
14.4.1. By Service
14.4.2. By Therapeutic Area
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2021
15.3. Company Profiles
15.3.1. Ashfield (UDG Healthcare plc)
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Syneos Health
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. IQVIA, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. GTS Solution
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. EVERSANA
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. MaBiCo
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Pharmaforce Ireland Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Sales Focus, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Amplity Health
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. PharmaLex GmbH
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
15.3.11. Star OUTiCO
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Company Financials
15.3.11.3. Growth Strategies
15.3.11.4. SWOT Analysis
15.3.12. NiSiPharm GmbH
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Company Financials
15.3.12.3. Growth Strategies
15.3.12.4. SWOT Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us